20 related articles for article (PubMed ID: 29070108)
1. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2020 Jul; 79(1):191-198.e3. PubMed ID: 32619469
[TBL] [Abstract][Full Text] [Related]
2. A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor.
Zhao W; Mo M; Yu J; Cheng S; Long G; Luo Z; Liang W; Yan C; Luo H; Sun B
Med Oncol; 2024 Apr; 41(5):113. PubMed ID: 38602586
[TBL] [Abstract][Full Text] [Related]
3. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
4. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
5. [Navitoclax Combined with Daunorubicin Promotes Apoptosis of Erythroleukemia Cell Lines K562, HEL and TF-1].
Duan YJ; Liu C; Chen XY; Wu WQ; Zheng JR; Zhang YC; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):724-730. PubMed ID: 32552927
[TBL] [Abstract][Full Text] [Related]
6. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe.
Shen JK; Du HP; Yang M; Wang YG; Jin J
Ann Hematol; 2009 Aug; 88(8):743-52. PubMed ID: 19139893
[TBL] [Abstract][Full Text] [Related]
7. A novel synthesized 3', 5'-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways.
Zhang YQ; Wen ZH; Wan K; Yuan D; Zeng X; Liang G; Zhu J; Xu B; Luo H
Biomed Pharmacother; 2018 Oct; 106():794-804. PubMed ID: 29990873
[TBL] [Abstract][Full Text] [Related]
8. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A; de Cárcer G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
[TBL] [Abstract][Full Text] [Related]
9. [Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].
Xu F; Chang CK; Li X; He Q; Wu LY; Zhang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1362-1366. PubMed ID: 29070108
[TBL] [Abstract][Full Text] [Related]
10. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]